BI 3032950 / Boehringer Ingelheim - LARVOL DELTA

A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Recruiting | N=45 ➔ 80 | Trial completion date: Feb 2028 ➔ Jul 2029 | Trial primary completion date: Jan 2026 ➔ Jul 2027

Enrollment change • Enrollment open • Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis (clinicaltrials.gov) - P2 | N=45 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Jun 2028 ➔ Feb 2028 | Trial primary completion date: May 2026 ➔ Jan 2026

Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis